1、Erlotinib mesylateCat. No.: HY-12008ACAS No.: 248594-19-6Molecular Formula: CHNOSMolecular Weight: 489.54Target: EGFR; AutophagyPathway: JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; AutophagyStorage: Please store the product under the recommended conditions in the COA.Solvent 36(19):2643-2654. J
2、 Invest Dermatol. 2018 Aug 3. pii: S0022-202X(18)32461-8. Mol Oncol. 2018 Mar;12(3):305-321. Oncotarget. 2017 Dec 2;8(68):112313-112329. Anal Chim Acta. 2018 Nov 22;1032:138-146.www.MedChemE2See more customer validations on www.MedChemEREFERENCES1. Moyer JD, et al. Induction of apoptosis and cell cy
3、cle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997 Nov 1;57(21):4838-48.2. Ali S, et al. Apoptosis-inducing effect of erlotinib is potentiated by 3,3-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Ca
4、ncer Ther, 2008, 7(6), 1708-1719.3. Marchetti S, et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.Mo
5、l Cancer Ther. 2008 Aug;7(8):2280-7.4. Adachi K, et al. Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats. J Toxicol Sci. 2010 Aug;35(4):503-14.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: techMedChemEAddress: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USAwww.MedChemE3
